

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. : 2241
Appln. No. : 10/734,930
Applicant : Evan B. Dreyer
Filed : 12/12/2003
TC/AU : 1612
Examiner : Zohreh A. Fay
Docket No. : 17322CON2CIP(AP) (1957205-00126)
Customer No. : 51957
Title : Calcium Blockers to Treat Proliferative Retinal Diseases

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Amendment to the Office Action dated August 6, 2008 on the above-identified application.

☒ Amendment (10 pages)

☒ The fee has been calculated as shown below.

<i>CLAIMS</i>	COLUMN A <i>Claims Remaining After Amendment</i>	COLUMN B <i>Highest Number Previously Paid</i>	COLUMN C <i>Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
<i>Total</i>	13	20	0	x \$50	\$.00
<i>Independent</i>	2	3	0	x \$210	\$.00
<input type="checkbox"/> First Presentation of Multiple Dep. Claim x \$280 =					\$.00
Time Extension Fees:					\$.00
Total Due:					\$.00

Please charge Deposit Account 01-0885 for any fees related to this Amendment.

Respectfully submitted,

/John E. Wurst/

John E. Wurst

Reg. No. 40,283

Attorney of Record

Date: November 6, 2008

Please send all inquires to:

John E. Wurst (T2-7H)

Allergan, Inc.

2525 Dupont Drive

Irvine, CA 92612

Telephone: 714/246-5475/Facsimile: 714/246-4249